Citigroup downgraded shares of Oxford Nanopore Technologies (LON:ONT – Free Report) to a buy rating in a research note published on Monday morning,Digital Look reports.
A number of other research analysts have also recently commented on the stock. Peel Hunt restated a “hold” rating and set a GBX 153 price target on shares of Oxford Nanopore Technologies in a research note on Monday, July 13th. Berenberg Bank lowered their price objective on Oxford Nanopore Technologies from GBX 230 to GBX 220 and set a “buy” rating on the stock in a research note on Monday, July 13th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a GBX 225 target price on shares of Oxford Nanopore Technologies in a report on Tuesday, May 26th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of GBX 212.60.
Check Out Our Latest Stock Report on Oxford Nanopore Technologies
Oxford Nanopore Technologies Price Performance
Insider Activity at Oxford Nanopore Technologies
In other Oxford Nanopore Technologies news, insider Nick Keher purchased 22,018 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of GBX 113 per share, for a total transaction of £24,880.34. Over the last 90 days, insiders purchased 22,774 shares of company stock valued at $2,578,100. 2.54% of the stock is owned by insiders.
Oxford Nanopore Technologies Company Profile
Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer.
Further Reading
- Five stocks we like better than Oxford Nanopore Technologies
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Oxford Nanopore Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Nanopore Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
